Compounds > fce 28260
Page last updated: 2024-12-07

fce 28260

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

(22RS-N-1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID132992
CHEMBL ID4540042
SCHEMBL ID2641279
MeSH IDM0234399

Synonyms (19)

Synonym
155651-56-2
fce-28260
4-azaandrost-1-ene-17-carboxamide, 3-oxo-n-(2,2,2-trifluoro-1-methyl-1-phenylethyl)-, (5alpha,17beta)-
hp9c5lm7nx ,
1h-indeno(5,4-f)quinoline-7-carboxamide, 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-n-(2,2,2-trifluoro-1-methyl-1-phenylethyl)-, (4ar-(4aalpha,4bbeta,6aalpha,7alpha,9abeta,9balpha,11abeta))-(partial)-
(22rs-n-1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
pnu 156765
2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-n-(2,2,2-trifluoro-1-methyl-1-phenylethyl)-1h-indeno(5,4-f)quinoline-7-carboxamide (4ar-(4aalpha,4bbeta,6aalpha,7alpha,9abeta,9balpha,11abeta))-(partial)-
unii-hp9c5lm7nx
fce 28260
(1s,3as,3bs,5ar,9ar,9bs,11as)-9a,11a-dimethyl-7-oxo-n-(1,1,1-trifluoro-2-phenylpropan-2-yl)-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
SCHEMBL2641279
DTXSID00894860
bdbm50517901
CHEMBL4540042 ,
faizuawlkohmop-zoixlqffsa-n
1h-indeno[5,4-f]quinoline-7-carboxamide, 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-n-(2,2,2-trifluoro-1-methyl-1-phenylethyl)-, (4ar,4bs,6as,7s,9as,9bs,11ar)-
(4ar,4bs,6as,7s,9as,9bs,11ar)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-n-(2,2,2-trifluoro-1-methyl-1-phenylethyl)-1h-indeno[5,4-f]quinoline-7-carboxamide
w-09704002

Research Excerpts

Overview

FCE 28260 is a novel inhibitor of 5 alpha-reductase (5 alpha R) This enzyme is responsible for the conversion of testosterone (T) to 5alpha-dihydrotestosterone (DHT)

ExcerptReferenceRelevance
"FCE 28260 is a novel inhibitor of 5 alpha-reductase (5 alpha R), the enzyme responsible for the conversion of testosterone (T) to 5 alpha-dihydrotestosterone (DHT). "( FCE 28260, a new 5 alpha-reductase inhibitor: in vitro and in vivo effects.
Briatico, G; Cominato, C; di Salle, E; Giudici, D; Iehlè, C; Nesi, M; Panzeri, A; Zaccheo, T, 1996)		3.18

Compound-Compound Interactions

ExcerptReferenceRelevance
" These data indicate a role for 5 alpha-reductase inhibitors in the therapy of prostate cancer, in combination with antiandrogens, in order to achieve adequate androgen blockade with minimal side effects."( Effect of the 5 alpha-reductase inhibitor PNU 156765, alone or in combination with flutamide, in the Dunning R3327 prostatic carcinoma model in rats.
di Salle, E; Giudici, D; Panzeri, A; Zaccheo, T, )		0.13

Dosage Studied

ExcerptRelevanceReference
" In adult male rats, FCE 28260 reduced prostatic DHT concentrations 6 h after oral dosing with a potency similar to that of finasteride (65% reduction at 1 mg/kg) but was found to be markedly more potent than the reference compound at 24 h (74% reduction in prostate DHT at 10 mg/kg, compared to 26% reduction induced by finasteride)."( FCE 28260, a new 5 alpha-reductase inhibitor: in vitro and in vivo effects.
Briatico, G; Cominato, C; di Salle, E; Giudici, D; Iehlè, C; Nesi, M; Panzeri, A; Zaccheo, T, 1996)		2.06
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)IC50 (µMol)0.02600.00170.48807.5000AID1573006; AID1573008
3-oxo-5-alpha-steroid 4-dehydrogenase 1 Rattus norvegicus (Norway rat)IC50 (µMol)0.01500.00427.468021.1000AID1573010
3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)IC50 (µMol)0.00970.00010.526710.0000AID1573007; AID1573009
3-oxo-5-alpha-steroid 4-dehydrogenase 2Rattus norvegicus (Norway rat)IC50 (µMol)0.01500.00037.329421.1000AID1573011
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
urogenital system development3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
liver development3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
androgen biosynthetic process3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
androgen catabolic process3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
sex determination3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
male gonad development3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
cellular response to starvation3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
response to xenobiotic stimulus3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
response to muscle activity3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
diterpenoid metabolic process3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
spinal cord development3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
hippocampus development3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
thalamus development3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
hypothalamus development3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
pituitary gland development3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
cerebral cortex development3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
cell differentiation3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
male genitalia development3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
female genitalia development3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
response to follicle-stimulating hormone3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
cellular response to insulin stimulus3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
serotonin metabolic process3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
progesterone metabolic process3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
response to estrogen3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
bone development3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
response to growth hormone3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
response to fungicide3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
cellular response to cAMP3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
cellular response to growth factor stimulus3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
cellular response to estradiol stimulus3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
cellular response to testosterone stimulus3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
cellular response to dexamethasone stimulus3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
cellular response to epinephrine stimulus3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
steroid biosynthetic process3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
androgen biosynthetic process3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
steroid catabolic process3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
cell-cell signaling3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
androgen metabolic process3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
male gonad development3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
response to xenobiotic stimulus3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
biphenyl metabolic process3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
dibenzo-p-dioxin metabolic process3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
phthalate metabolic process3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
hippocampus development3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
hypothalamus development3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
cell differentiation3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
male genitalia development3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
female genitalia development3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
response to nutrient levels3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
response to follicle-stimulating hormone3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
response to testosterone3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
response to peptide hormone3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
response to steroid hormone3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
bone development3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
testosterone biosynthetic process3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
steroid biosynthetic process3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
3-oxo-5-alpha-steroid 4-dehydrogenase activity3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
electron transfer activity3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
amide binding3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
3-oxo-5alpha-steroid 4-dehydrogenase (NADP+) activity3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
NADPH binding3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
3-oxo-5-alpha-steroid 4-dehydrogenase activity3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
protein binding3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
testosterone dehydrogenase [NAD(P)] activity3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
amide binding3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
3-oxo-5alpha-steroid 4-dehydrogenase (NADP+) activity3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membrane3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
neuronal cell body3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
perinuclear region of cytoplasm3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
cell body fiber3-oxo-5-alpha-steroid 4-dehydrogenase 1Homo sapiens (human)
endoplasmic reticulum membrane3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
neuronal cell body3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
cell body fiber3-oxo-5-alpha-steroid 4-dehydrogenase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1573011Inhibition of type 2 5alpha reductase in rat prostate2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
AID1573006Inhibition of human type 1 5alpha reductase2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
AID1573009Inhibition of type 2 5alpha reductase in human prostate2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
AID1573008Inhibition of type 1 5alpha reductase in human prostate2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
AID1573010Inhibition of type 1 5alpha reductase in rat prostate2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
AID1573007Inhibition of human type 2 5alpha reductase2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (50.00)18.2507
2000's1 (25.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.77 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
fentanyl
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.		3.2710anilide;
monocarboxylic acid amide;
piperidines		adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
dehydroepiandrosterone
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.. dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.		2.021017-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid		androgen;
human metabolite;
mouse metabolite
dihydrotestosterone
Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.		1.991017beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
senecioic acid
senecioic acid: structure. 3-methylbut-2-enoic acid : A methyl-branched fatty acid that is but-2-enoic acid bearing a methyl substituent at position 3.		3.2710alpha,beta-unsaturated monocarboxylic acid;
methyl-branched fatty acid;
monounsaturated fatty acid;
short-chain fatty acid		plant metabolite
finasteride
Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.		3.53203-oxo steroid;
aza-steroid;
delta-lactam		androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
artemisinin
(+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		3.2710organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
methanesulfonamide
[no description available]		3.2710
trifluoromethylsulfonamide
trifluoromethylsulfonamide: RN given refers to parent		3.2710
enkephalin, leucine
Enkephalin, Leucine: One of the endogenous pentapeptides with morphine-like activity. It differs from MET-ENKEPHALIN in the LEUCINE at position 5. Its first four amino acid sequence is identical to the tetrapeptide sequence at the N-terminal of BETA-ENDORPHIN.. Leu-enkephalin : A pentapeptide comprising L-tyrosine, glycine, glycine, L-phenylalanine and L-leucine residues joined in sequence by peptide linkages. It is an endogenous opioid peptide produced in vertebrate species, including rodents, primates and humans that results from decomposition of proenkephalin or dynorphin and exhibits antinociceptive properties.		3.2710pentapeptide;
peptide zwitterion		analgesic;
delta-opioid receptor agonist;
human metabolite;
mu-opioid receptor agonist;
neurotransmitter;
rat metabolite
dutasteride
Dutasteride: A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.. dutasteride : An aza-steroid that is inasteride in which the tert-butyl group is replaced by a 2,5-bis(trifluoromethyl)phenyl group. A synthetic 4-azasteroid, dutasteride is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase, an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland.		3.2710(trifluoromethyl)benzenes;
aza-steroid;
delta-lactam		antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
vilazodone
vilazodone : A 1-benzofuran that is 5-(piperazin-1-yl}-1-benzofuran-2-carboxamide having a (5-cyanoindol-3-yl)butyl group attached at position N-4 on the piperazine ring. Used for the treatment of major depressive disorder.		3.27101-benzofurans;
indoles;
monocarboxylic acid amide;
N-alkylpiperazine;
N-arylpiperazine;
nitrile		antidepressant;
serotonergic agonist;
serotonin uptake inhibitor
dpc 423
[no description available]		3.2710
samarium
sphingomyelin 16:0 : A sphingomyelin in which the total number of carbons contained in the sphingoid base and fatty acyl groups is 16 with zero double bonds.. sphingomyelin d18:1/16:0 : A sphingomyelin d18:1 in which the fatty acyl group contains 16 carbons and is fully saturated.. N-hexadecanoylsphingosine-1-phosphocholine : A sphingomyelin 34:1 in which the N-acyl group and sphingoid base are specified as hexadecanoyl and sphingosine respectively.		3.2710sphingomyelin d18:1/16:0mouse metabolite
ch 4987655
[no description available]		3.2710
pristinamycin iib
virginiamycin M2: structure in first source		3.2710
ConditionIndicatedRelationship StrengthStudiesTrials
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.0210